Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
AstraZeneca (NASDAQ:AZN) and its partner
Sanofi (NASDAQ:SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this
Motley Fool Live video
recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.
Keith Speights: Let s stay on AstraZeneca. we ve been talking about some bad news that the drugmaker has experienced. But AstraZeneca actually had some good news this week.